Olmesartan Medoxomil E Idroclorotiazide Teva Italia (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil combined with hydrochlorothiazide is indicated for the management of high blood pressure within the renin‑angiotensin‑aldosterone system pathway.

• Hypertension: lowers systolic and diastolic blood pressure when monotherapy is insufficient.
• Hypertensive patients with fluid retention: adds diuretic effect to improve volume control.
• Cardiovascular risk reduction: contributes to lower risk of stroke and myocardial infarction by maintaining target blood‑pressure levels.

• Olmesartan medoxomil selectively blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis. The combined actions reduce peripheral vascular resistance and extracellular fluid volume, resulting in lowered arterial pressure.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Fatigue.
• Increased urination.
• Electrolyte disturbances (e.g., low potassium).
• Mild gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypotension.
• Acute kidney injury.
• Hyperkalemia or severe electrolyte imbalance.
• Angio‑edema.
• Liver function abnormalities.
• Blood cell disorders such as neutropenia.

Before initiating therapy, consider patient‑specific factors and monitor appropriately.

• Renal impairment: adjust monitoring of kidney function and electrolytes.
• Hepatic disease: use with caution and observe liver enzymes.
• Electrolyte balance: monitor potassium and sodium levels regularly.
• Pregnancy: avoid use; teratogenic risk is not established.
• Concomitant diuretics: assess for additive electrolyte loss.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil/hydrochlorothiazide may interact with several drug classes; clinical judgment is required.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): increased risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• NSAIDs (high dose): may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Lithium: increased lithium levels, risk of toxicity.
• ACE inhibitors or other ARBs: additive hypotensive effect.
• Antifungal azoles (e.g., ketoconazole): may increase olmesartan plasma concentrations.